Slide 1: H1 FY26 Result Presentation
H1 FY26 Result Presentation 27 February 2026 Mach7 Technologies | ASX: M7T
Slide 2: Our Vision
OUR VISION To be the global imaging EMR. We win by completing the patient picture with the patient’s pictures, better than anyone else. * Electronic Medical Record (EMR).
Slide 3: Agenda
Agenda 1 Business Overview Teri Thomas | CEO 2 H1 FY26 Results Daniel Lee | CFO 3 Outlook Unless otherwise stated, all dollar values are in Australian dollars (AUD) 3
Slide 4: Business Overview
‘ : ~\ Aimac7 Business Overview
Slide 5: RESET
Slide 6: H1 FY26 operational achievements
H1 FY26 operational achievements Reset phase largely complete – now in build and deliver mode 1 Expanded product suite with launch of Flamingo architecture opening new revenue pathways; first customer secured in December 2025. 2 Transformed sales and marketing model with clear ownership across new c
Slide 7: Moving from archive to architecture
Moving from archive to architecture Executing deliberate reset positioning imaging as core layer of patient record. Clear Disciplined Rebuilt Sharpened operating cost commercial product model base engine roadmap Foundations for durable profitable growth in place. 7
Slide 8: Commercial transformation continues
Commercial transformation continues Building a performance driven culture that values top talent and disciplined execution. Overhauled customer facing Re-energised sales Reallocation of areas and marketing resources Flight Crew model and focus on Rebuilt sales organisation with new Streamlined HQ lo
Slide 9: Expanded product suite: Flamingo Architecture
Expanded product suite: Flamingo Architecture eUnity Enterprise Vendor Neutral Archive Flamingo Architecture Diagnostic Viewer ✓ Consolidate ALL images across the enterprise ✓ AI enablement within the software PLUS ✓ Zero footprint HTML-5 viewer; 100% fidelity ✓ Modular and flexible platform for cre
Slide 10: Flamingo update
Flamingo update Flamingo pipeline: positive progress and realistic expectations. Modular & Strong strategic selling fit • Supports Drive • First customer enterprise imaging Pipeline framing signed in Q2 FY26 sustainable ARR strategy Focus on pipeline • Can be sold to • Enables AI, quality and execut
Slide 11: RSNA 2025
RSNA 2025 • Targeting lead generation quality over quantity – early qualification, higher win probability • Deeper engagement with select partners • Strong validation of archive to architecture 11
Slide 12: Quantifying growth trends
Quantifying growth trends Enterprise Imaging AI in Medical Market Growth Imaging Expansion Enterprise imaging market AI in medical imaging market valued at US$2.1B in 2024 is projected to grow rapidly at 20- expected to reach US$4.1B by 35% CAGR from US$1.3B in 2024. 2030 with 12% CAGR. Global AI Ma
Slide 13: Ideal Customer Profile (ICP)
Ideal Customer Profile (ICP) • Pain points – Data fragmentation, slow image access, vendor lock-in. • Key buying drivers – Data independence, AI readiness, fast diagnostics, lower cost of ownership. • Key decision makers – CIO, CMIO, Head of Imaging / Radiology, VP of IT. • We know AMCs - Mach7 alre
Slide 14: Differentiators
Differentiators End-to-end modular architecture for data independence & sovereignty 1 Vendor Neutral Architecture allows customers full control and unrestricted access to their data, with modular components. AI & workflow automation drives advanced orchestration 2 Intelligent rules-based routing, me
Slide 15: H2 FY26 priorities
H2 FY26 priorities Sales momentum • Sign new customer contracts • Increase visibility of expansion opportunities within install base • Invest in additional resources to support Asia sales opportunities Execution discipline • Flight Crew Pods fully operational • Enhanced accountability via “week plan
Slide 16: H1 FY26 Results
( | Ue _o H1 FY26 Results = —
Slide 17: H1 FY26 Financial Review
H1 FY26 Financial Review Predominantly recurring revenue, lower cost base, strong balance sheet 1 Recurring revenue base represents 85% of total revenue, 78% OPEX. 32% 2 Reduced operating expenses by 6% significant 10% 3 Strong financial position with cash of A$18.5M and no debt providing flexibilit
Slide 18: H1 FY26 Financial Summary
H1 FY26 Financial Summary A$13.7M A$11.6M A$26.1M A$23.0M Revenue Recurring Revenue2 CARR3 ARR4 Run Rate -A$4.1M or -23% on PCP1 -A$1.1M or -8% on PCP -A$3.4M or -12% on PCP -A$0.3M or -2% on PCP 85% of total revenue (PCP: 71%) 78% OPEX (1H FY25: 80%) A$14.8M -A$2.3M -A$2.7M A$18.5M Operating Expens
Slide 19: ARR run-rate has remained stable
ARR run-rate has remained stable • Revenue of A$13.7M, down 23% on PCP (H1 FY25: A$17.7M) due to lower capital sales, customer churn and decline in professional services revenue. • Recurring Revenue of A$11.6M, down 8% on PCP, accounting for 85% of total revenue and representing 78% of OPEX. • Profe
Slide 20: Rebuilding commercial organisation
Rebuilding commercial organisation New sales leadership and marketing capability in place • Sales Orders of A$10.0M (TCV1) compared to A$16.2M in H1 FY25. • Annual Recurring Revenue (ARR) Sales Orders of A$8.5M (85% of sales orders) representing subscription 49% 58% 32% and maintenance and support f
Slide 21: Strong cost discipline as implement reset
Strong cost discipline as implement reset Earnings (A$M)1 H1 26 H1 25 $ Change % Change • OPEX reduced by 6% in H1 FY26 Revenue 13.7M 17.7M (4.1M) (23%) reflecting disciplined cost management Cost of sales (1.1M) (1.0M) (0.1M) 2% and early benefits of the commercial and organisational reset. Gross M
Slide 22: Outlook
~ : : \ Aimact7 a >| glist 7 "3 43 ‘ aN Outlook
Slide 23: Introducing Todd Stallard
Introducing Todd Stallard Profitable growth through improved sales, marketing and partner management. Commercial Excellence • Driving a disciplined, scalable, data-driven revenue engine across all channels. • Aligning product, engineering, finance, sales, and customer teams to unlock growth, optimis
Slide 24: Outlook
Outlook • As H2 FY26 progresses, Mach7 has a refined strategy, stronger operational foundation and improving commercial momentum. • Mach7 is confident in its strategy and execution, underpinned by a re-energised sales and partner model, expanded marketing capability and early traction for its Flamin
Slide 25: Contact Us
Contact Us Investor Relations, Mach7 Françoise Debelak +61 (0) 412 292 977 ir@mach7t.com Registered Office: Suite 2, Level 11, 385 Bourke St, Melbourne, VIC 3000 This document was authorised for release to the ASX by Teri Thomas, Managing Director and Chief Executive Officer Mach7 Technologies
Slide 26: Disclaimer
Disclaimer “Forward looking” statements Summary of information: This presentation contains general and background information about Mach7 Risks: An investment in M7T securities is subject to investment and other known and unknown risks, Technologies Limited (“M7T”) activities current as at the date